HKSE · 1801.HK
Innovent Biologics, Inc.
HK$81.65+HK$0.05 (+0.06%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.55% below the high.
Loading market information…
HKSE · 1530.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 03:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
3SBio Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.26% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
3SBio Inc.’s forward annual dividend is HK$0.25 per share, paid annual. The forward yield is 1.82% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
3SBio Inc.’s next earnings report is currently expected on Mar 30, 2027, with estimated earnings per share of HK$0.58. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow 3SBio Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:30 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2023 |
|---|
| Mar 21, 2024 |
| HK$0.26-41.38% vs estimate |
| HK$4.46B-2.21% vs estimate |
| Q2 2023 | Aug 24, 2023 | HK$0.43+14.75% vs estimate | HK$4.09B+6.0% vs estimate |
|---|
| Q4 2022 | Mar 22, 2023 | HK$0.41+1.1% vs estimate | HK$4.30B-1.89% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$81.65+HK$0.05 (+0.06%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.55% below the high.
HK$436.80-HK$1.00 (-0.23%)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 22.35% below the high.
HK$83.50HK$0.00 (0.0%)
Akeso, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.47% below the high.
HK$49.68-HK$0.24 (-0.48%)
Shanghai Henlius Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.96% below the high.
HK$17.55-HK$0.13 (-0.74%)
Zai Lab Limited’s quoted price sits in the upper half of its reported 52-week range, 18.07% below the high.
HK$11.46-HK$0.21 (-1.8%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 29.26% below the high.
HK$18.12-HK$0.48 (-2.58%)
Mabwell-b’s quoted price sits in the lower half of its reported 52-week range, 37.9% below the high.
HK$5.05+HK$0.31 (+6.55%)
CStone Pharmaceuticals’s quoted price sits in the lower half of its reported 52-week range, 51.54% below the high.
